Jupiter Wellness (NASDAQ: JUPW), a developer of cannabidiol (“CBD”) based therapeutics and wellness products, today announced initiation of a clinical study of its CaniSun(TM) sunscreen lotion for the treatment of actinic keratosis (“AK”), the most common precancer that forms on the skin as a result of exposure to ultraviolet (“UV”) rays. The clinical study’s primary objective is to evaluate Canisun as a treatment for AK by reviewing the efficacy in both treatment and prophylaxis of patients. The study, to be conducted by Applied Biology (Irvine, California), will recruit an estimated 116 adults diagnosed with AK. “I am excited to work with Applied Biology in the clinical evaluation of Canisun, which may have the potential to offer relief from this side effect to patients’ exposure to UV rays,” said Brian John, CEO of Jupiter Wellness. “Initiating this AK study represents an important opportunity for Jupiter Wellness to obtain patient data and evaluate any potential benefits of our sunscreen products.”
To view the full press release, visit https://ibn.fm/3JYZz
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”) based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For more information, visit the company’s website at www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.